- Home
- KEP vs EXAS Comparison
KEP vs EXAS Comparison
Compare KEP & EXAS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KEP
- EXAS
- Stock Information
- Founded
- KEP 1961
- EXAS 1995
- Country
- KEP South Korea
- EXAS United States
- Employees
- KEP N/A
- EXAS N/A
- Industry
- KEP Electric Utilities: Central
- EXAS Medical Specialities
- Sector
- KEP Utilities
- EXAS Health Care
- Exchange
- KEP Nasdaq
- EXAS Nasdaq
- Market Cap
- KEP 9.4B
- EXAS 10.5B
- IPO Year
- KEP N/A
- EXAS N/A
- Fundamental
- Price
- KEP $7.61
- EXAS $49.26
- Analyst Decision
- KEP
- EXAS Strong Buy
- Analyst Count
- KEP 0
- EXAS 17
- Target Price
- KEP N/A
- EXAS $72.31
- AVG Volume (30 Days)
- KEP 144.7K
- EXAS 1.9M
- Earning Date
- KEP 03-03-2025
- EXAS 02-19-2025
- Dividend Yield
- KEP N/A
- EXAS N/A
- EPS Growth
- KEP N/A
- EXAS N/A
- EPS
- KEP 4.40
- EXAS N/A
- Revenue
- KEP $70,353,349,144.00
- EXAS $2,758,867,000.00
- Revenue This Year
- KEP $6.97
- EXAS $12.09
- Revenue Next Year
- KEP $4.70
- EXAS $11.24
- P/E Ratio
- KEP $3.47
- EXAS N/A
- Revenue Growth
- KEP 8.48
- EXAS 10.37
- 52 Week Low
- KEP $6.68
- EXAS $40.62
- 52 Week High
- KEP $9.55
- EXAS $79.62
- Technical
- Relative Strength Index (RSI)
- KEP 61.60
- EXAS 33.51
- Support Level
- KEP $7.04
- EXAS $45.94
- Resistance Level
- KEP $7.70
- EXAS $51.75
- Average True Range (ATR)
- KEP 0.10
- EXAS 2.13
- MACD
- KEP 0.05
- EXAS -0.30
- Stochastic Oscillator
- KEP 86.57
- EXAS 32.20
About KEP Korea Electric Power Corporation
Korea Electric Power Corp is an electric utility company in which the government of South Korea holds a controlling stake. The firm operates in the following segments: Transmission and distribution, Electric power generation (Nuclear), Electric power generation (Non-Nuclear), Plant maintenance & engineering service, and Others. The majority of the energy produced by the company comes from its nuclear and coal-fired assets. Korea Electric Power generates revenue through the Transmission and distribution segment.
About EXAS Exact Sciences Corporation
Exact Sciences, headquartered in Madison, Wisconsin, provides cancer screening and diagnostic test products in the United States and internationally. Exact's Cologuard screening test, a noninvasive stool-based DNA test, is a precancer screening test for colorectal cancer. The company also competes in the precision oncology market with Oncotype DX, a suite of tissue-based genomic tests for estimating recurrence risk and likelihood of benefit from chemotherapy for breast and colon cancer, and OncoExTra, a liquid-based comprehensive genomic profiling test. It is also developing liquid biopsy tests for molecular residual disease, colorectal cancer screening, and multicancer screening.